Clinical trials · Riverside–San Bernardino, CA
Acute Myeloid Leukemia, in Relapse clinical trials in Riverside–San Bernardino
We’re tracking 41 recruiting acute myeloid leukemia, in relapse studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Loma Linda, CaliforniaAges Up to 22 years - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Orange, CaliforniaAges 1–21 - NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Orange, CaliforniaAges 4 weeks–21 years - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Orange, CaliforniaAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Orange, CaliforniaAges 1–18 - NCT04811560RecruitingPhase 1/Phase 2
Study of a targeted medicine for certain relapsed leukemia
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
Orange, CaliforniaAges 2 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Irvine, CaliforniaAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Irvine, CaliforniaAges 18 years+ - NCT06146257RecruitingPhase 1
Study of GLB-001 for Relapsed or Refractory AML or High-Risk MDS
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Irvine, CaliforniaAges 18 years+ - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Duarte, CaliforniaAges Up to 21 years - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT06575296RecruitingPhase 1
Revumenib after stem cell transplant for acute leukemia
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
Duarte, CaliforniaAges 2 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Duarte, CaliforniaAges 18 years+ - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Duarte, CaliforniaAges 4 weeks+
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Acute Myeloid Leukemia, in Relapse trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting acute myeloid leukemia, in relapse studies listed above.
- City of Hope · 14 studies
- University of California, Irvine · 4 studies
- USC Norris Comprehensive Cancer Center · 3 studies
- Children's Hospital Los Angeles · 2 studies
- Children's Hospital of Orange County · 2 studies
- Children's Hospital of Orange County Main Campus - Orange
- Children's Hospital Orange County
- City of Hope Cancer Center (Data collection only)
What taking part in a acute myeloid leukemia, in relapse study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting acute myeloid leukemia, in relapse studies in California.
Common questions
- Are there acute myeloid leukemia, in relapse clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 41 recruiting acute myeloid leukemia, in relapse studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute myeloid leukemia, in relapse study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute myeloid leukemia, in relapse trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute myeloid leukemia, in relapse studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.